Does the presence of an intact primary increase the risk of nonelective colorectal surgery in patients treated with bevacizumab?
Nancy N BaxterR SutradharFahima DossaL FuP RochonA C WeiE D KennedyC C EarlePublished in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2020)
Bevacizumab is associated with a low but meaningful risk for serious gastrointestinal complications, necessitating vigilance, particularly among patients with an intact primary tumour.
Keyphrases